Meeting
2019 ASCO Annual Meeting
A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.
Authors
Soong June Bae
Gangnam Severance Hospital, Seoul, South Korea
Soong June Bae , Chang-Ik Yoon , So Eun Park , Chi Hwan Cha , Dooreh Kim , Janghee Lee , Sung Gwe Ahn , Hyung Seok Park , Youngup Cho , Joon Jeong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 587)
DOI
10.1200/JCO.2019.37.15_suppl.587
Abstract #
587
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
First Author: Giampaolo Bianchini
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2014 ASCO Annual Meeting
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
First Author: Joseph B. Babigumira
Poster
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
First Author: Teng Zhu